LT3656393T - Liofilizuoti citotoksinių dipeptidų preparatai - Google Patents
Liofilizuoti citotoksinių dipeptidų preparataiInfo
- Publication number
- LT3656393T LT3656393T LTEP19215699.0T LT19215699T LT3656393T LT 3656393 T LT3656393 T LT 3656393T LT 19215699 T LT19215699 T LT 19215699T LT 3656393 T LT3656393 T LT 3656393T
- Authority
- LT
- Lithuania
- Prior art keywords
- lyophilized preparation
- cytotoxic dipeptides
- dipeptides
- cytotoxic
- lyophilized
- Prior art date
Links
- 108010016626 Dipeptides Proteins 0.000 title 1
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A61K38/105—Bombesin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1150371 | 2011-04-28 | ||
| US201161535126P | 2011-09-15 | 2011-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3656393T true LT3656393T (lt) | 2022-12-12 |
Family
ID=47071620
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP12718949.6T LT2701720T (lt) | 2011-04-28 | 2012-04-25 | Liofilizuotas citotoksinių dipeptidų preparatas |
| LTEP19215699.0T LT3656393T (lt) | 2011-04-28 | 2012-04-25 | Liofilizuoti citotoksinių dipeptidų preparatai |
| LTPA2022529C LTC2701720I2 (enExample) | 2011-04-28 | 2022-12-16 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP12718949.6T LT2701720T (lt) | 2011-04-28 | 2012-04-25 | Liofilizuotas citotoksinių dipeptidų preparatas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTPA2022529C LTC2701720I2 (enExample) | 2011-04-28 | 2022-12-16 |
Country Status (29)
| Country | Link |
|---|---|
| US (8) | US20140128462A1 (enExample) |
| EP (4) | EP3656393B1 (enExample) |
| JP (1) | JP6042412B2 (enExample) |
| KR (2) | KR101808895B1 (enExample) |
| CN (2) | CN108096563A (enExample) |
| AU (1) | AU2012247545B2 (enExample) |
| BR (2) | BR112013027584B1 (enExample) |
| CA (2) | CA2833500C (enExample) |
| CY (2) | CY1119453T1 (enExample) |
| DK (3) | DK2701720T3 (enExample) |
| ES (2) | ES2930140T3 (enExample) |
| FI (1) | FIC20230004I1 (enExample) |
| FR (1) | FR23C1000I2 (enExample) |
| HR (2) | HRP20171523T1 (enExample) |
| HU (3) | HUE037863T2 (enExample) |
| IL (3) | IL228889A0 (enExample) |
| LT (3) | LT2701720T (enExample) |
| LU (1) | LUC00291I2 (enExample) |
| MX (1) | MX345102B (enExample) |
| NL (1) | NL301206I2 (enExample) |
| NO (1) | NO2023004I1 (enExample) |
| PL (3) | PL2701720T3 (enExample) |
| PT (2) | PT3656393T (enExample) |
| RS (3) | RS56462B1 (enExample) |
| RU (1) | RU2597154C2 (enExample) |
| SI (2) | SI3228319T1 (enExample) |
| SM (3) | SMT202200450T1 (enExample) |
| WO (1) | WO2012146625A1 (enExample) |
| ZA (1) | ZA201308765B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2930140T3 (es) | 2011-04-28 | 2022-12-07 | Oncopeptides Ab | Preparación liofilizada de dipéptidos citotóxicos |
| JP5827178B2 (ja) * | 2012-06-05 | 2015-12-02 | 北越紀州製紙株式会社 | セルロース多孔質体及びその製造方法 |
| SMT202000058T1 (it) * | 2012-10-26 | 2020-03-13 | Oncopeptides Ab | Preparazioni liofilizzate di melfalan flufenammide |
| HUE047813T2 (hu) * | 2012-10-26 | 2020-05-28 | Oncopeptides Ab | Melphalan-flufenamidot tartalmazó liofilizált készítmények |
| GB201507903D0 (en) | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| GB201521217D0 (en) | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
| US10369077B2 (en) * | 2017-05-31 | 2019-08-06 | Adienne Pharma & Biotech Sa | Multi chamber flexible bag and methods of using the same |
| US10507165B2 (en) | 2017-05-31 | 2019-12-17 | Adienne Pharma & Biotech Sa | Multi chamber flexible bag and methods of using same |
| CA3116198A1 (en) * | 2018-10-18 | 2020-04-23 | Oncopeptides Ab | Compounds containing deuterium |
| EP3946309A1 (en) | 2019-04-03 | 2022-02-09 | Oncopeptides AB | Treatment of al amyloidosis with melflufen |
| GB201905477D0 (en) * | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
| WO2021053185A1 (en) | 2019-09-20 | 2021-03-25 | Oncopeptides Ab | Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma |
| US11503829B2 (en) * | 2020-05-08 | 2022-11-22 | Gjb Applied Technologies, Inc. | Pesticidal compositions and related methods |
| AU2021327164A1 (en) * | 2020-08-19 | 2023-03-16 | Cellact Pharma Gmbh | Etoposide toniribate formulation |
| US12077809B2 (en) | 2021-04-27 | 2024-09-03 | Enplas Corporation | Freeze-dried structure and producing method thereof |
| GB202109894D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| JP2024524552A (ja) | 2021-07-08 | 2024-07-05 | オンコペプティデス エービー | 多発性骨髄腫の治療に使用するためのメルフルフェン |
| GB202109895D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109896D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| KR102757193B1 (ko) * | 2021-10-19 | 2025-01-21 | 단국대학교 천안캠퍼스 산학협력단 | 피리미딘-2,4-다이온 유도체를 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물 |
| GB202204171D0 (en) | 2022-03-24 | 2022-05-11 | Oncopeptides Ab | Novel formulations |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB750155A (en) | 1953-03-17 | 1956-06-13 | Nat Res Dev | Substituted alanines |
| GB8727157D0 (en) * | 1987-11-19 | 1987-12-23 | Wellcome Found | Pharmaceutical formulations |
| JP3176716B2 (ja) | 1991-06-21 | 2001-06-18 | 武田薬品工業株式会社 | 溶解性が向上した難水溶性薬物組成物 |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6992207B2 (en) * | 2000-06-13 | 2006-01-31 | Oncopeptides Ab | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
| SE0002202D0 (sv) * | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| EP1438019A1 (en) | 2001-10-24 | 2004-07-21 | PARI GmbH Spezialisten für effektive Inhalation | Kit for the preparation of a pharmaceutical composition |
| NZ534378A (en) * | 2002-02-22 | 2006-10-27 | Schering Corp | Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same |
| US6780324B2 (en) * | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US20040034099A1 (en) * | 2002-06-27 | 2004-02-19 | Ramsey Beverly J. | Pharmaceutical composition |
| US20050152979A1 (en) * | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
| ES2349472T3 (es) | 2004-08-12 | 2011-01-03 | Schering Corporation | Formulación estable de interferón pegilado. |
| RS50510B (sr) * | 2004-10-29 | 2010-03-02 | Pharma Mar S.A., Sociedad Unipersonal | Formulacije koje sadrže ekteinascidin i disaharid |
| EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| KR101143596B1 (ko) | 2006-07-07 | 2012-05-11 | 길리애드 사이언시즈, 인코포레이티드 | 신규의 피리다진 화합물 및 이의 용도 |
| DK2101731T3 (en) | 2006-11-21 | 2018-04-16 | Jina Pharmaceuticals Inc | ENDOXIFEN FOR USING CANCER TREATMENT |
| CN101584669B (zh) * | 2009-06-19 | 2010-12-29 | 江苏奥赛康药业有限公司 | 美法仑冻干粉针剂 |
| WO2011078782A1 (en) * | 2009-12-22 | 2011-06-30 | Oncopeptides Ab | A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer |
| AR077384A1 (es) | 2010-07-05 | 2011-08-24 | Eriochem Sa | Una formulacion farmaceutica inyectable de melfalano. |
| US20140038996A1 (en) * | 2011-04-15 | 2014-02-06 | Janssen Pharmaceutica Nv | Freeze Dried Drug Nanosuspensions |
| ES2930140T3 (es) | 2011-04-28 | 2022-12-07 | Oncopeptides Ab | Preparación liofilizada de dipéptidos citotóxicos |
| SMT202000058T1 (it) | 2012-10-26 | 2020-03-13 | Oncopeptides Ab | Preparazioni liofilizzate di melfalan flufenammide |
-
2012
- 2012-04-25 ES ES19215699T patent/ES2930140T3/es active Active
- 2012-04-25 PL PL12718949T patent/PL2701720T3/pl unknown
- 2012-04-25 DK DK12718949.6T patent/DK2701720T3/en active
- 2012-04-25 RS RS20171002A patent/RS56462B1/sr unknown
- 2012-04-25 US US14/113,768 patent/US20140128462A1/en not_active Abandoned
- 2012-04-25 AU AU2012247545A patent/AU2012247545B2/en active Active
- 2012-04-25 RS RS20221059A patent/RS63747B1/sr unknown
- 2012-04-25 PT PT192156990T patent/PT3656393T/pt unknown
- 2012-04-25 PT PT127189496T patent/PT2701720T/pt unknown
- 2012-04-25 RU RU2013152751/15A patent/RU2597154C2/ru active
- 2012-04-25 KR KR1020137031096A patent/KR101808895B1/ko active Active
- 2012-04-25 CN CN201810054866.9A patent/CN108096563A/zh active Pending
- 2012-04-25 BR BR112013027584-7A patent/BR112013027584B1/pt active IP Right Grant
- 2012-04-25 JP JP2014506850A patent/JP6042412B2/ja active Active
- 2012-04-25 HU HUE12718949A patent/HUE037863T2/hu unknown
- 2012-04-25 DK DK17173249.8T patent/DK3228319T3/da active
- 2012-04-25 SM SM20220450T patent/SMT202200450T1/it unknown
- 2012-04-25 RS RS20201030A patent/RS60719B1/sr unknown
- 2012-04-25 WO PCT/EP2012/057577 patent/WO2012146625A1/en not_active Ceased
- 2012-04-25 SM SM20170459T patent/SMT201700459T1/it unknown
- 2012-04-25 HU HUE19215699A patent/HUE060783T2/hu unknown
- 2012-04-25 SI SI201231829T patent/SI3228319T1/sl unknown
- 2012-04-25 MX MX2013012545A patent/MX345102B/es active IP Right Grant
- 2012-04-25 CA CA2833500A patent/CA2833500C/en active Active
- 2012-04-25 ES ES12718949.6T patent/ES2642676T3/es active Active
- 2012-04-25 KR KR1020177035122A patent/KR102122416B1/ko active Active
- 2012-04-25 EP EP19215699.0A patent/EP3656393B1/en active Active
- 2012-04-25 BR BR122019017088-6A patent/BR122019017088B1/pt active IP Right Grant
- 2012-04-25 LT LTEP12718949.6T patent/LT2701720T/lt unknown
- 2012-04-25 CN CN201280019920.7A patent/CN103547279A/zh active Pending
- 2012-04-25 EP EP22191185.2A patent/EP4122482A1/en active Pending
- 2012-04-25 LT LTEP19215699.0T patent/LT3656393T/lt unknown
- 2012-04-25 DK DK19215699.0T patent/DK3656393T3/da active
- 2012-04-25 HR HRP20171523TT patent/HRP20171523T1/hr unknown
- 2012-04-25 HR HRP20221355TT patent/HRP20221355T1/hr unknown
- 2012-04-25 CA CA3024230A patent/CA3024230C/en active Active
- 2012-04-25 PL PL19215699.0T patent/PL3656393T3/pl unknown
- 2012-04-25 SI SI201231086T patent/SI2701720T1/sl unknown
- 2012-04-25 SM SM20200447T patent/SMT202000447T1/it unknown
- 2012-04-25 EP EP17173249.8A patent/EP3228319B1/en active Active
- 2012-04-25 EP EP12718949.6A patent/EP2701720B1/en active Active
- 2012-04-25 PL PL17173249T patent/PL3228319T3/pl unknown
-
2013
- 2013-10-15 IL IL228889A patent/IL228889A0/en active IP Right Grant
- 2013-11-21 ZA ZA2013/08765A patent/ZA201308765B/en unknown
-
2016
- 2016-08-01 US US15/225,323 patent/US10322182B2/en active Active
-
2017
- 2017-10-12 CY CY20171101070T patent/CY1119453T1/el unknown
-
2019
- 2019-03-19 IL IL265457A patent/IL265457B/en active IP Right Grant
- 2019-04-12 US US16/382,276 patent/US10543274B2/en active Active
- 2019-06-28 US US16/457,102 patent/US20200009252A1/en not_active Abandoned
- 2019-12-19 US US16/721,639 patent/US10869928B2/en active Active
-
2020
- 2020-02-03 IL IL272429A patent/IL272429B/en unknown
- 2020-07-22 US US16/935,372 patent/US11344622B2/en active Active
- 2020-08-12 CY CY20201100749T patent/CY1123242T1/el unknown
-
2022
- 2022-04-27 US US17/730,398 patent/US11896668B2/en active Active
- 2022-12-13 LU LU00291C patent/LUC00291I2/fr unknown
- 2022-12-13 NL NL301206C patent/NL301206I2/nl unknown
- 2022-12-16 LT LTPA2022529C patent/LTC2701720I2/lt unknown
-
2023
- 2023-01-04 FR FR23C1000C patent/FR23C1000I2/fr active Active
- 2023-01-16 NO NO2023004C patent/NO2023004I1/no unknown
- 2023-01-16 HU HUS2300005C patent/HUS2300005I1/hu unknown
- 2023-01-19 FI FIC20230004C patent/FIC20230004I1/fi unknown
-
2024
- 2024-07-19 US US18/400,055 patent/US20240358838A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2300005I1 (hu) | Citotoxikus dipeptidek liofilizált készítménye | |
| HUS1900047I1 (hu) | Liofilizált liposzómák | |
| PL2675480T3 (pl) | Sposoby otrzymywania koniugatów | |
| ZA201306118B (en) | Lyophilized formulations | |
| SG10201604667YA (en) | Pharmaceutical preparation | |
| SI2691083T1 (sl) | Farmacevtski sestavek sitagliptina | |
| CY2022038I2 (el) | Λυοφιλοποιημενη παρασκευη κυτταροτοξικων διπεπτιδιων | |
| GB201105298D0 (en) | Pharmaceutical preparation | |
| IL231664A0 (en) | Novel peptide histories as antibiotics | |
| EP2684869A4 (en) | PREPARATION OF 3-MERCAPOTOPROPIONATES | |
| PL2691119T3 (pl) | Preparat farmaceutyczny | |
| GB201407689D0 (en) | Pharmaceutical compositions of antihypertensives |